Louis Brenner, president and chief operating officer at Allena Pharmaceuticals (NASDAQ: [[ticker:ALNA]]), will become CEO starting Feb. 1. He will also join the Newton, MA, company’s board of directors. Allena co-founder and current CEO Alexey Margolin will shift to a new role as chairman of the board. Launched in 2011, Allena went on to raise $96 million in a 2017 IPO. Allena’s lead drug candidate, reloxaliase, is in two Phase 3 studies testing it as a treatment for hyperoxaluria, a rare metabolic disease that has no FDA-approved treatments.
